NRx is excited about the most recent report published by the Israeli Institute of Biological Research on the BriLife® vaccine.
The scientific report shows serologic response against the Omicron variant in patients vaccinated during the phase 2 clinical trial of BriLife® against Sars-CoV-2 coronavirus. Ten of 13 vaccinated subjects demonstrated detectable neutralizing antibody against Omicron.
IIBR submits first scientific report on serologic response against Omicron variant in patients vaccinated with BriLife in phase two trials. Ten of 13 vaccinated subjects demonstrated detectable neutralizing antibody against Omicron.
The report can be found here: https://www.medrxiv.org/content/10.1101/2021.11.22.21266673v2